<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01070940</url>
  </required_header>
  <id_info>
    <org_study_id>EBP.FHC.1.2009</org_study_id>
    <secondary_id>2009-017001-11</secondary_id>
    <nct_id>NCT01070940</nct_id>
  </id_info>
  <brief_title>L-NMMA Dose-response Study in Healthy Subjects</brief_title>
  <official_title>L-NMMA's Effect on Renal and Cardiovascular Variables in Healthy Subjects. A Randomized, Placebo-controlled Crossover Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regional Hospital Holstebro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regional Hospital Holstebro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of different levels of nitric oxide
      inhibition on blood pressure and arterial stiffness in healthy subjects. L-NMMA, an inhibitor
      of the nitric oxide synthase, is administered as bolus injection followed by continuous
      infusion, and is expected to raise blood pressure and arterial stiffness according to L-NMMA
      dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>6 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GFR</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Stiffness</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional excretion of sodium</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional excretion of potassium</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma renin concentration</measure>
    <time_frame>6 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma angiotensin II</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma aldosterone</measure>
    <time_frame>6 hour</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Isotonic saline infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous L-NMMA dose 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous L-NMMA dose 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous L-NMMA dose 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NG-monomethyl-L-arginine (L-NMMA)</intervention_name>
    <description>3 mg/kg IV priming dose + 2 mg/kg/hr IV infusion for 1 hour</description>
    <arm_group_label>Intravenous L-NMMA dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NG-monomethyl-L-arginine (L-NMMA)</intervention_name>
    <description>6 mg/kg IV priming dose + 4 mg/kg/hr IV infusion for 1 hour</description>
    <arm_group_label>Intravenous L-NMMA dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NG-monomethyl-L-arginine (L-NMMA)</intervention_name>
    <description>4.5 mg/kg IV priming dose + 3 mg/kg/hr IV infusion for 1 hour</description>
    <arm_group_label>Intravenous L-NMMA dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Isotonic saline solution IV priming dose + IV infusion for 1 hour</description>
    <arm_group_label>Isotonic saline infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males

          -  Age 18-35 years

          -  BMI 18.5-30.0

        Exclusion Criteria:

          -  Tobacco or illicit drug use

          -  Current use of any prescription or non-prescription drugs

          -  Alcohol abuse

          -  History of heart failure, lever failure, chronic kidney disease or cerebral insult

          -  Diabetes

          -  Clinical or paraclinical signs of infection

          -  Pathologic ECG

          -  Ambulatory blood pressure &gt;140/90 mmHg

          -  Abnormal blood or urin screening tests
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Larsen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Departments of Medical Research, Holstebro Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank H Christensen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Departments of Medical Research, Holstebro Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erling B Pedersen, Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Departments of Medical Research, Holstebro Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesper N Bech, Ph.d.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Departments of Medical Research, Holstebro Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departments of Medical Research</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2010</study_first_submitted>
  <study_first_submitted_qc>February 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2010</study_first_posted>
  <last_update_submitted>February 18, 2011</last_update_submitted>
  <last_update_submitted_qc>February 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Thomas Larsen, M.D.</name_title>
    <organization>Departments of Medical Research, Holstebro Hospital</organization>
  </responsible_party>
  <keyword>L-NMMA</keyword>
  <keyword>blood pressure</keyword>
  <keyword>arterial stiffness</keyword>
  <keyword>pulse wave velocity</keyword>
  <keyword>augmentation index</keyword>
  <keyword>dose-response</keyword>
  <keyword>healthy subjects</keyword>
  <keyword>GFR</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>omega-N-Methylarginine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

